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To the Editor,
The goal of healthcare systems is to provide the optimal 
treatment to the patient. However, an exact diagnosis is 
the prerequisite for an effective treatment. It was esti-
mated that 70%–80% of all healthcare decisions that 
influence the clinical decision making involve one or 
more laboratory investigations, with individual’s treat-
ment decisions and the monitoring of their response to 
treatment, often dependent on laboratory-based diag-
nostics [1]. However, as financial resources are limited, 
economic issues must be considered, in order to achieve 
best value for the patient, making our healthcare system 
as efficient as possible and fundable for future gen-
erations. A reduction of errors during the laboratory 
process is one way to reduce costs, since these errors 
might not only lead to possibly harmful consequences 
for the patient, but also causes repeated specimen col-
lection and analyses, thus resulting in an unjustifiable 
increase in costs. It is well documented, that within the 
total laboratory process, errors most frequently occur in 
the extranalytical phase with the vast majority within 
preanalytical processes [2]. Hemolytic blood specimen 
are the foremost preanalytic cause of sample rejec-
tion, which, according to a survey of 453 laboratories, 
occurs five times more frequently than the second most 
cited reason, insufficient specimen quantity to perform 
the requested test [3]. We therefore tried to investigate 
the economic impact of hemolysis to our budget and 
screened current literature for respective calculations, 
aiming to perform similar calculations with our own 
data. However, to the best of our knowledge, accord-
ing calculations are rare [4, 5]. We therefore aimed to 
quantify the consequential costs of hemolytic blood 
specimen, and to properly illustrate the financial conse-
quences of a change in hemolysis rates. We calculated in 
a way, so that further investigators are able to apply our 
findings to their own setting.
We divided these expenses into material, person-
nel and analytical costs. As blood collection can be per-
formed by needle, butterfly system or IV catheter, three 
variants of material costs were calculated, always includ-
ing one tube holder and two collection tubes. To calcu-
late personnel costs, we estimated the time needed for a 
blood collection, including all steps from test ordering 
to preparation for transportation. As blood collection in 
our hospital is performed by the nursing staff, a mean 
of the respective hourly wages was used for calculation 
[6]. Analytical costs were calculated using the two most 
commonly used scales of charges of medical labora-
tory analyses in Germany [7, 8]. These sums reflect the 
chargeable prize and not just the laboratory costs of 
the specific parameter. However, we chose to use these 
numbers, since laboratory costs depend on reagent prize, 
 personnel costs and costs for the analytical device, all of 
which varying substantially between laboratories. As also 
the chargeable amounts in the official two scales differ 
from each other, we calculated costs and hypothetical 
cost reductions for both, displaying them as a respective 
range of costs. As harmonization in hemolysis measure-
ment as well as respective cut-off values are still missing, 
we chose to refer to the hemolysis index (HI), which is 
measured by the COBAS analyzers (Roche, Switzerland), 
with a HI of 1 being equal to a concentration of 1 mg/dL 
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of free hemoglobin [9, 10]. As HI cut-off for each param-
eter measureable on these analyzers, we used the official 
documents and packaging inserts of the manufacturer. 
These cut-offs define a HI value for each analyte, which 
corresponds to the point where the test analyte differs by 
more than 10% from the respective baseline. In order for 
the reader of this article to apply our findings to their own 
setting and to be able to calculate the economic impact of 
hemolysis reduction within their hospital, we refrained 
from hemolysis categories like mild, intermediate and 
severe. We rather grouped hemolysis into 16 HI ranges, 
and calculated the respective analysis costs (Table 1). To 
estimate overall costs of hemolysis in a clinical setting, 
we additionally set up a hypothetical situation. In this 
setting, which approximately reflects the situation in a 
common hospital, we assumed 20,000 laboratory orders 
monthly where blood collection is performed by the 
nursing staff using a butterfly system. Hemolysis rates 
were estimated as realistic as possible. Also, we simu-
lated a 10% reduction of hemolysis within this setting, to 
be able to estimate the financial benefit of efforts towards 
this goal (Table 2).
Material costs for blood collection using a needle, a 
butterfly system or an IV catheter were €0.19, €0.35 and 
€0.76, respectively. Personnel costs for a nurse spending 
estimated 10 min on average on one blood collection were 
€4.75. Analyses costs for the different hemolysis groups 
rise with increasing HI, since more parameters get affected 
(Table 1). When applying hypothetical percentages for 
each hemolysis group, the financial burden would range 
from €67,570 to €122,077, depending on the scale of charge 
in use. After applying additional percentages, illustrating 
an assumed reduction of 10% in hemolysis rates, the cost 
reduction ranges accordingly from €6757 to €12,208 per 
month (Table 2). These calculations presume that every 
parameter listed in the respective HI group in Table 1 was 
measured in every laboratory order and therefore had to 
be reanalyzed. In a clinical setting this rarely would be 
the case and therefore the overall costs would diminish 
respectively.
As hemolytic blood specimen are the most common 
reason for sample rejection and analyses repetition, a 
reduction in hemolysis rates should be one of the top 
goals of a laboratory to be able to provide the highest 
possible quality in analytics and to prevent possible 
harm to the patient due to inappropriate further inves-
tigations or even wrong treatment. Despite the quality 
issue, the outcome of our work impressively elucidates 
the financial impact of this economically underrated 
issue and reveals a possibility of cost saving to the 
healthcare system.
Jacobs et  al. estimated monthly analytical costs of 
£4355 (∼€6000) due to repeated measurements of hemo-
lytic specimen, based on 60 emergency admissions per 
day, not taking material or personnel costs into account 
[4]. Lippi et  al. calculated overall material and person-
nel costs of €19,535 for 38,009 samples which had to be 
recollected due to hemolysis over a 12-month period, 
accounting for 22.8% of all samples collected in this time 
[5]. When trying to project these numbers on our hypo-
thetical setting of 20,000 orders per month, monthly 
analytical costs of Jacobs et  al. are approximately 
€66,667, whereas material and personnel costs by the 
work of Lippi et  al. sum up to €2348 per month. Sepa-
rately calculating costs in our own study yielded €58,348 
for material and personnel, and a range from €9223 to 
€63,729 for analytical costs. This demonstrates clearly, 
that the financial impact of hemolysis is highly depend-
ent on the respective setting and the extent of hemolyis. 
We hope that our work can serve as basis for calculation 
of consequential costs due to hemolytic specimen in dif-
ferent settings.
As limitation to this work, it should be mentioned, 
that we focused on frequently ordered analytes in clini-
cal chemistry. Analytes from other laboratory special-
ties, which are also influenced by hemolysis, such as 
coagulation parameters, were not taken into account, 
as we had no defined HI cut-off levels [11]. Also, as 
described above, the analytic costs used in our setting 
reflect the chargeable prize, rather than sole labora-
tory costs. Additionally, our calculations might not be 
adaptable to settings using different analytical meas-
urements and estimations of hemolysis, apart from 
the one described above, as there is no harmonization 
between these measurements yet [9]. Also the analyti-
cal interference of hemolysis differs between the tests 
and reagents in use. Finally, we only calculated primary 
costs of hemolysis. Secondary costs have to be consid-
ered, but are very hard to put in numbers. Such costs 
could be caused by prolonged time to diagnosis and 
subsequent delayed treatment onset with a respectively 
extended hospital stay or by further inappropriate 
investigations.
In conclusion, the financial importance of hemolysis 
has been demonstrated. To further reduce hemolysis on 
a larger scale, harmonization of hemolysis measurements 
and defined HI cut-offs are desperately needed. One first 
approach to compare hemolysis rates all over the world 
could be the quality indicators project of the IFCC Working 
Group “Laboratory Errors and Patient Safety” [12, 13]. We 
want to urge each laboratory to measure hemolysis as a 
quality indicator and to further depict how a respective 
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reduction of hemolysis rates would contribute not only 
to their quality improvement, but also to their economic 
situation.
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